Cancer Antigen 125 in Ovarian Cancer Surveillance: A Decision Analysis Model
1
Division of Gynecologic Oncology, University of Ottawa, Ottawa, ON, Canada
2
Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2007, 14(5), 167-172; https://doi.org/10.3747/co.2007.144
Submission received: 5 July 2007
/
Revised: 5 August 2007
/
Accepted: 5 September 2007
/
Published: 1 October 2007
Abstract
We used decision analysis techniques with Markov cohort modeling to examine the role of cancer antigen 125 (CA-125) in follow-up surveillance strategies among patients with advanced ovarian cancer. Utilities were derived from a societal perspective. Using quality-adjusted life years (QALYs) as the outcome variable, the value of CA-125 monitoring for asymptomatic women with ovarian cancer was found to be reduced as compared with a strategy that includes CA-125 testing. Decisions to include CA-125 in surveillance strategies for ovarian cancer patients should be made after discussion with full disclosure of the preference-sensitive nature of CA-125. The model demonstrates that preferences and perspective can influence decisions in cancer care.
Keywords:
decision analysis; CA-125; preferences
Share and Cite
MDPI and ACS Style
Hopkins, M.L.; Coyle, D.; Le, T.; Fung, M.F.K.; Wells, G. Cancer Antigen 125 in Ovarian Cancer Surveillance: A Decision Analysis Model. Curr. Oncol. 2007, 14, 167-172. https://doi.org/10.3747/co.2007.144
AMA Style
Hopkins ML, Coyle D, Le T, Fung MFK, Wells G. Cancer Antigen 125 in Ovarian Cancer Surveillance: A Decision Analysis Model. Current Oncology. 2007; 14(5):167-172. https://doi.org/10.3747/co.2007.144
Chicago/Turabian StyleHopkins, M. Laura, D. Coyle, T. Le, M. Fung Kee Fung, and G. Wells. 2007. "Cancer Antigen 125 in Ovarian Cancer Surveillance: A Decision Analysis Model" Current Oncology 14, no. 5: 167-172. https://doi.org/10.3747/co.2007.144
